Ophthalmology at Pitt

Founded in 1787, the University of Pittsburgh has a distinguished legacy of driving innovation in ophthalmology research and clinical care. Today, Pitt ranks #6 in NIH funding and #9 in National Eye Institute funding among educational institutions. Our Fox Center for Vision Restoration stands as the nation's first comprehensive, multidisciplinary program dedicated to ocular regenerative medicine, while the UPMC Vision Institute delivers cutting-edge gene and cell therapies. From inherited retinal degenerations to age-related macular degeneration, Pitt's researchers are pioneering treatments that restore and preserve sight.

Featured Collaborative Research Opportunities
Novel Small Molecules for Rhodopsin-Related Retinitis Pigmentosa

Research Area: Retinitis Pigmentosa | Small Molecule Therapeutics | Inherited Retinal Degeneration

Description: Researchers have identified novel small molecules that restore homeostasis of rhodopsin mutants associated with retinitis pigmentosa, one of the most common inherited causes of blindness. The team is now testing these retinal protective agents in other blinding disease models, including congenital stationary night blindness, demonstrating broad therapeutic potential.

Ideal Partner Profile: Pharmaceutical and biotech companies developing treatments for inherited retinal diseases, small molecule therapeutic developers, and rare disease-focused partners.

Discuss This Opportunity
Gene Therapy and Gene Editing for Retinal Diseases

Research Area: Gene Therapy | CRISPR/Cas9 | Viral Vector Engineering | Retinal Disease

Description: Scientists are engineering viral vectors with enhanced capabilities to deliver therapeutic genes to the retina with unprecedented precision. Additionally, the team is implementing CRISPR/Cas9 gene editing to directly rewrite the genome, offering potential cures for previously untreatable inherited retinal diseases.

Ideal Partner Profile: Gene therapy companies, CRISPR therapeutic developers, ophthalmology-focused biotechs, and viral vector manufacturing partners.

Discuss This Opportunity
Cytokine-Based Therapies for Photoreceptor Protection

Research Area: Retinal Degeneration | Neuroprotection | Age-Related Macular Degeneration

Description: Research has shown that endogenously expressed cytokines like leukemia inhibitory factor (LIF) are crucial for preventing or delaying photoreceptor and RPE cell death under chronic stress conditions. This work reveals new therapeutic targets for both inherited retinal degenerations and age-related macular degeneration.

Ideal Partner Profile: Companies developing neuroprotective therapies, biologics developers, and partners focused on AMD or inherited retinal diseases.

Discuss This Opportunity
Stem Cell Therapy for Corneal Scarring

Research Area: Corneal Disease | Stem Cell Therapy | Regenerative Medicine

Description: Researchers have identified that human corneal stromal stem cells express anti-fibrotic microRNAs (miRNA-29a and 381-5p), providing a robust cell selection tool for stem cell therapy of corneal scarring. This breakthrough offers new hope for patients with vision loss from corneal injury or disease.

Ideal Partner Profile: Regenerative medicine companies, cell therapy developers, and ophthalmology therapeutics partners focused on corneal disease.

Discuss This Opportunity

License Pitt Technologies

Browse Our Portfolio of Available Innovations

View Technologies
Connect With Our Team

Featured Collaborative Research Opportunities

National Leadership in Vision Research

#

6
NIH funding among educational institutions (2023)

#

9
National Eye Institute funding for ophthalmology (2023)
1st
National program dedicated to ocular regenerative medicine (Fox Center for Vision Restoration)
World-Class Facilities & Centers
UPMC Vision Institute

A comprehensive hub for vision innovation and clinical care

The UPMC Vision Institute represents a unique collaborative space bringing together clinicians, researchers, educators, and industry partners to advance vision care.

Distinctive Features:

  • Gene and Cell Therapy Delivery – Clinical-grade facilities for ocular gene and cell therapies
  • Fully Mocked-Up Apartment – Innovative training environment where patients can relearn critical life skills in a realistic home setting
  • 3-D Street Lab – Simulated city streets, offices, and meeting rooms to help patients with low vision navigate their surroundings
  • Industry Collaboration Space – Dedicated areas for partnering with companies on device testing, therapeutic development, and clinical validation
Learn More
Louis J. Fox Center for Vision Restoration

The nation's first comprehensive ocular regenerative medicine program

A pioneering multidisciplinary research and clinical program dedicated to restoring sight through tissue regeneration, transplantation, and technology.

Focus Areas:

  • Tissue regeneration and stem cell therapies
  • Retinal and corneal transplantation approaches
  • Vision restoration technologies including retinal prostheses
  • Integration of biological and technological solutions
Learn More
Core Vision Research at the Eye & Ear Institute

State-of-the-art core facilities supporting cutting-edge research

Core Capabilities:

  • Imaging Acquisition & Analysis – Advanced retinal and corneal imaging platforms
  • Tissue Culture & Histology – Specialized facilities for ocular tissue research
  • Genomics, Proteomics & Molecular Biology – Comprehensive molecular analysis capabilities
  • Flow Cytometry & Cell Sorting – High-precision cell analysis and sorting
Learn More
Systems Pharmacology Lab of Retinal Degeneration

Translating molecular discoveries into therapeutic solutions

Focused on retinitis pigmentosa and rhodopsin mutations, this lab has identified novel small molecules that restore cellular homeostasis and is expanding therapeutic approaches to other blinding diseases.

Learn More

From Basic Discovery to Clinical Translation

Core Research Capabilities:

Novel small molecule discovery and development

Viral vector engineering and precision gene delivery

Retinal and corneal regenerative approaches

Artificial vision technologies

Direct genome correction for inherited diseases

Adaptive optics, OCT, and multimodal imaging platforms

Real-world training environments and adaptation technologies

Comprehensive models of inherited and acquired retinal diseases

Resources & Next Steps
Find Faculty Expertise

Connect with our world-class vision researchers advancing gene therapy, regenerative medicine, and therapeutic development.

Search Faculty Directory
Explore Available Technologies

Browse our portfolio of licensable ophthalmology innovations—from gene therapies to diagnostic tools.

View Technologies
Start a Conversation

Ready to explore an ophthalmology partnership? Our team can connect you with the right expertise and facilities.

Contact Our Team
OIE_OIEP Wordmark

Let's Advance Vision Restoration Together

Whether you're interested in collaborative research, technology licensing, clinical trials, or access to our unique facilities like the UPMC Vision Institute's 3-D Street Lab, our Industry Partnerships team is ready to help.

Office of Innovation and Entrepreneurship
partner@pitt.edu